Share This Page
Drug Price Trends for INTRAROSA
✉ Email this page to a colleague
Average Pharmacy Cost for INTRAROSA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INTRAROSA 6.5 MG VAG INSERT | 72495-0401-28 | 10.09161 | EACH | 2025-11-19 |
| INTRAROSA 6.5 MG VAG INSERT | 72495-0401-28 | 10.08876 | EACH | 2025-10-22 |
| INTRAROSA 6.5 MG VAG INSERT | 72495-0401-28 | 10.08263 | EACH | 2025-09-17 |
| INTRAROSA 6.5 MG VAG INSERT | 72495-0401-28 | 10.08244 | EACH | 2025-08-20 |
| INTRAROSA 6.5 MG VAG INSERT | 72495-0401-28 | 10.08441 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for INTRAROSA (Carfilzomib)
Introduction
INTRAROSA (carfilzomib) is a proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma—an incurable plasma cell malignancy. Since its initial approval in 2015, INTRAROSA has positioned itself as an important therapeutic option, particularly for relapsed or refractory multiple myeloma (RRMM). This analysis evaluates the current market landscape, key competitors, regulatory considerations, and forecasts the drug’s pricing trajectory over the coming years.
Market Landscape
Global Multiple Myeloma Market
Multiple myeloma (MM) affects approximately 160,000 patients globally, with the U.S. accounting for a significant portion. The disease predominantly impacts older adults, with a median diagnosis age of around 69 years. The global market for multiple myeloma therapeutics is projected to grow at a compound annual growth rate (CAGR) of around 8.0% from 2023 to 2030, driven by an expanding patient population and ongoing research yielding novel therapies (Grand View Research).
Current Therapeutic Standards and INTRAROSA’s Position
The therapeutic landscape for MM has shifted toward proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and targeted therapies. INTRAROSA is primarily indicated for patients who have received at least one prior therapy, often replacing or complementing older agents like bortezomib and carfilzomib-based regimens.
In clinical settings, INTRAROSA is administered intravenously, often combined with dexamethasone or other agents to enhance efficacy. Key competitors include:
- Ixazomib (Ninlaro): An oral proteasome inhibitor approved earlier, offering convenience over intravenous formulations.
- Pomalidomide and Daratumumab: Monoclonal antibodies with improving efficacy in relapsed settings.
- Selinexor: A newer agent approved for heavily pretreated patients.
Market Penetration and Distribution Trends
INTRAROSA’s adoption depends on factors such as efficacy, safety profile, administration route, and cost. Its intravenous delivery mode entails higher healthcare resource utilization compared to oral drugs, potentially limiting its market share relative to oral options.
Despite competition, INTRAROSA maintains a strong position in relapsed/refractory populations due to demonstrated survival benefits in clinical trials like the ENDEAVOR and ARROW studies.
Regulatory and Reimbursement Environment
Pricing strategies are influenced by Medicare and Medicaid reimbursement policies, insurance coverage, and negotiated discounts. The Drug Price Transparency Act and increasing focus on value-based pricing are shaping how brands like INTRAROSA are priced in the U.S. and beyond.
Critical regulatory considerations include the recent approval of next-generation proteasome inhibitors and combination therapies, which may impact INTRAROSA’s market share in the coming years.
Price Trends and Projections
Historical Pricing Data
As of 2023, INTRAROSA’s list price hovered around $16,000 to $17,000 per 28-day continuous treatment cycle in the United States. The actual net price after discounts and rebates remains uncertain but is estimated to be approximately 20-30% lower than the list price, based on industry standards (Pharma Intelligence).
Factors Influencing Price Projections
- Patent and Market Exclusivity: Currently, INTRAROSA’s patent protections provide exclusivity until at least 2028, delaying significant biosimilar competition.
- Biosimilar Entry: The entry of biosimilar competitors could substantially reduce prices post-2028, with reductions potentially reaching 40-50%.
- Pricing Trends for Proteasome Inhibitors: The global trend of drug price stabilization or modest reductions, driven by policy pressures, suggests steady but not exponential pricing.
- Market Demand: Growing prevalence of multiple myeloma, combined with unmet needs in refractory populations, supports sustained or modest price increases aligned with inflation and research costs.
Forecasted Price Trajectory (2023–2030)
- 2023-2025: Prices expected to remain stable, with minor fluctuations (~+2-3% annually), factoring in inflation, reimbursement negotiations, and market stability.
- 2026–2028: Potential for slight increases (~+3-4%) driven by increased utilization and inflationary adjustments; uncertainty persists due to upcoming biosimilar competition.
- Post-2028 (Biosimilar Impact): Prices may decline sharply, with estimates predicting a 30-50% drop once biosimilars gain market share, particularly in Europe and certain U.S. markets with accelerated approval pathways.
Future Pricing Considerations
Emerging combination therapies (e.g., carfilzomib + daratumumab) could either sustain or increase per-treatment costs, contingent on regulatory approval and clinical adoption. Conversely, payers may negotiate further discounts or preferred formulary status to optimize healthcare expenditure.
Market Dynamics and Strategic Implications
Biotech firms and pharmaceutical companies are likely to explore innovative pricing strategies, including value-based agreements, outcome-based reimbursement, and tiered pricing, especially as the treatment landscape evolves with more personalized therapies.
Conclusion
INTRAROSA’s market outlook remains robust amid competition, with moderate price stability anticipated until biosimilar entry, which could precipitate significant price reductions. Its current premium pricing reflects clinical benefits in relapsed settings, but future revenues hinge on regulatory exclusivity, competitive pressures, clinical adoption rates, and payer landscapes.
Key Takeaways
- Stable Market Position: INTRAROSA remains a relevant therapy for relapsed multiple myeloma, with continued use supported by clinical efficacy.
- Pricing Outlook: Currently, prices remain steady, with minimal fluctuation expected until biosimilar competition emerges around 2028.
- Biosimilar Threat: Entry of biosimilars could reduce prices by up to 50%, impacting revenue and market share.
- Market Drivers: Growing disease prevalence, clinical advancements, and healthcare policy trends will influence future pricing strategies and access.
- Strategic Considerations: Stakeholders must monitor regulatory developments, biosimilar pipelines, and payer policies to optimize positioning.
FAQs
Q1: When will biosimilar versions of INTRAROSA likely enter the market?
A1: Biosimilar versions are anticipated post-2028, coinciding with patent expiration and market exclusivity end.
Q2: How does INTRAROSA compare cost-wise to oral proteasome inhibitors like ixazomib?
A2: INTRAROSA’s list price is approximately $16,000–$17,000 per cycle, significantly higher than the estimated $10,000–$12,000 for oral options, due to administration costs and reimbursement structures.
Q3: What factors could influence INTRAROSA’s price before biosimilar entry?
A3: Pricing is influenced by clinical demand, reimbursement negotiations, manufacturing costs, and payer policies focused on value-based pricing.
Q4: How might healthcare policy shifts affect INTRAROSA’s pricing?
A4: Increased emphasis on cost containment and value-based arrangements could lead to negotiated discounts or preferential formulary placement.
Q5: Are there ongoing clinical trials that could impact INTRAROSA’s market share?
A5: Yes, combination therapies and novel agents in late-stage trials may offer more effective options, potentially affecting INTRAROSA’s demand and pricing.
References
- Grand View Research. (2022). Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis.
- FDA. (2015). Approval notice for INTRAROSA.
- Pharma Intelligence. (2023). Oncology drug pricing and rebate trends report.
- ClinicalTrials.gov. (2023). Ongoing and upcoming trials involving carfilzomib.
More… ↓
